Drug Design Development and Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2025-07-17 ms8000000453181943 来自辽宁省

偏重的研究方向：网药;药理;中药
经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。

4 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2024-07-25 148817e2m02暂无昵称来自江苏省

偏重的研究方向：药物;药物治疗
经验分享：大家好，请问大家1A1状态一般持续多久呀

123 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2025-05-20 匿名用户

拒稿说不收bib这种文章类型

13 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2025-03-31 ms8000000453181943 来自北京

偏重的研究方向：网药;中药
经验分享：修回后编辑做决定都半个多月了正常吗

10 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2022-02-16 审稿人爸爸求求您

1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的

156 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2023-09-20 41982559 来自广东省

偏重的研究方向：药理
经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。

177 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2024-08-17 ms9000001638905587 来自吉林省

请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，

92 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2024-08-31 汉库克来自湖北省

偏重的研究方向：治疗;药物;药物治疗
经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估

51 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2024-08-16 ms5000001216482403 来自山东省

审稿速度:6.0 | 投稿命中率:50.0
经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误

111 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2273701, encodeId=6ed522e370131, content=偏重的研究方向：网药;药理;中药 经验分享：经验分享：原始研究，相比工作量更看重创新性。从投稿到录用8个月，前4个月非常快，补实验一个月，回复完外审的意见。剩下4个月就是挤牙膏式的编辑提问，回复了四次，都是统计学的问题，每次一个问题，我很快就回复过去，然后编辑要2-3周才会回复我，就这样拖了4个月，其实他的问题本可以一次说完的，非常简单的问题，有的问题像是有模版，总体感觉好坏参半吧。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Thu Jul 17 10:50:47 CST 2025, time=2025-07-17, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2216779, encodeId=68d12216e799f, content=偏重的研究方向：药物;药物治疗 经验分享：大家好，请问大家1A1状态一般持续多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6ac5308712, createdName=148817e2m02暂无昵称, createdTime=Thu Jul 25 14:00:49 CST 2024, time=2024-07-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2265827, encodeId=1e89226582eee, content=拒稿说不收bib这种文章类型, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Tue May 20 09:12:26 CST 2025, time=2025-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2258592, encodeId=db7522585923a, content=偏重的研究方向：网药;中药 经验分享：修回后编辑做决定都半个多月了正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e89494357, createdName=ms8000000453181943, createdTime=Mon Mar 31 21:48:30 CST 2025, time=2025-03-31, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1194025, encodeId=8aeb119402561, content=1e状态好几天，原始数据文件太大，上传不了，大家都是怎么上传的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54675539272, createdName=审稿人爸爸求求您, createdTime=Wed Feb 16 14:13:10 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158717, encodeId=d2192158e175c, content=偏重的研究方向：药理 经验分享：请问大家除了wb外，是否需要上传试剂盒等数据吗？我想上传但没找到这部分的作者须知。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=feb55120331, createdName=41982559, createdTime=Wed Sep 20 14:52:33 CST 2023, time=2023-09-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2220819, encodeId=22352220819ed, content=请问一下我在此期刊撤过稿一次，我又有一篇文章，再投的话会不会受到偏见，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38259426047, createdName=ms9000001638905587, createdTime=Sat Aug 17 14:11:06 CST 2024, time=2024-08-17, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2223379, encodeId=303222233e930, content=偏重的研究方向：治疗;药物;药物治疗 经验分享：老师们，faers数据挖掘接受吗？faers+预测模型+风险评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fc22196834, createdName=汉库克, createdTime=Sat Aug 31 19:35:34 CST 2024, time=2024-08-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2220418, encodeId=972b222041871, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2.27投稿，7.16接受，8.15见刊。审稿慢一点，接收后速度快，还会帮助修改一些错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04149161451, createdName=ms5000001216482403, createdTime=Fri Aug 16 09:45:32 CST 2024, time=2024-08-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2210592, encodeId=e70d221059270, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：药理 经验分享： 3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程 6 March 2024 Submission created 20 March 2024 Compliance checks completed 21 March 2024 Awaiting evaluation 25 March 2024 Compliance checks completed 27 March 2024 Awaiting evaluation 28 March 2024 Compliance checks completed 2 April 2024 Awaiting re-submission 2 April 2024 Revised submission received 3 April 2024 Editorial checks completed moved to Compliance checks 20 March 2024 Peer review selection 9 April 2024 Peer review invitations sent 13 April 2024 First peer reviewer allocated 26 April 2024 First report returned 3 May 2024 Second or more peer reviewer reports returned Editorial decision - revisions 3 May 2024 Report sent to the Editor-in-Chief 4 May 2024 Report: revise with changes 14 May 2024 Resubmission pending 1 June 2024 Resubmitted manuscript received 5 June 2024 Processing revised manuscript 7 June 2024 Sent to Editor-in-Chief for acceptance or rejection 5 June 2024 Query regarding revised manuscript Invoicing 8 June 2024 Invoice to follow for article processing charge subject to final decision 10 June 2024 Accepted for publication, invoice sent, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01f78282923, createdName=ms5000000946930121, createdTime=Wed Jun 19 00:04:56 CST 2024, time=2024-06-19, status=1, ipAttribution=天津)]

2024-06-19 ms5000000946930121 来自天津

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：药理
经验分享：
3.6投稿，细胞实验文，后期补材料啥的，差不多3周之后正式进入流程
6 March 2024

Submission created

20 March 2024

Compliance checks completed

21 March 2024

Awaiting evaluation

25 March 2024

Compliance checks completed

27 March 2024

Awaiting evaluation

28 March 2024

Compliance checks completed

2 April 2024

Awaiting re-submission

2 April 2024

Revised submission received

3 April 2024

Editorial checks completed moved to Compliance checks

20 March 2024

Peer review selection

9 April 2024

Peer review invitations sent

13 April 2024

First peer reviewer allocated

26 April 2024

First report returned

3 May 2024

Second or more peer reviewer reports returned

Editorial decision - revisions
3 May 2024

Report sent to the Editor-in-Chief

4 May 2024

Report: revise with changes

14 May 2024

Resubmission pending

1 June 2024

Resubmitted manuscript received

5 June 2024

Processing revised manuscript

7 June 2024

Sent to Editor-in-Chief for acceptance or rejection

5 June 2024

Query regarding revised manuscript

Invoicing
8 June 2024

Invoice to follow for article processing charge subject to final decision

10 June 2024

Accepted for publication, invoice sent

97 6 举报

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务